NCT02924987 - Effect of Aflibercept (Eylea®) in the Management of Bevacizumab (Avastin®) Resistant Diabetic Macular Edema | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

November 30, 2017

Study Completion Date

November 30, 2017

Conditions

Diabetic Macular Edema

Interventions

DRUG

Aflibercept Injection

Intravitreal injections of 0.05 mL (2mg) of Aflibercept will be injected. The intravitreal between the first 5 treatments sessions is 4 weeks, and the interval for the following treatment sessions up to week 52 is 8 weeks.

Trial Locations (1)

H1T2M4

RECRUITING

Maisonneuve Rosemont Hospital, Montreal